Clinical Trials Browser

Breast Carcinoma In Situ × Tablets × 1 year × Clear all

NCT06033092 2025-08-28

TOLERANT

Phase 2 Active not recruiting

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating